Sponsor

Centre Leon Berard

France 28 Rue Laennec, 69008 Lyon, France

About the sponsor

Clinical research at Centre Leon Berard includes a broad set of advanced and metastatic solid tumors, with particular attention to gastroesophageal adenocarcinoma, pancreatic adenocarcinoma, renal cell carcinoma, and gynecological cancers. The portfolio also covers rare and molecularly defined cancers, including tumors with FGFR2b overexpression and MSI/dMMR or EBV-associated disease.

Metastatic gastric and esophageal cancer
Pancreatic cancer
Renal cell carcinoma
Molecularly selected solid tumors

Research also extends to patients with recurrent or treatment-resistant disease, reflecting interest in cancers requiring targeted and immunologic strategies.

About Specializations

Centre Leon Berard runs clinical trials in conditions such as Gastrointestinal stromal tumour, Neoplasm, Gastric cancer, Sarcoma, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

25 clinical trials

Squamous cell carcinoma of the hypopharynx+1

Recruiting

Evaluation of Lymphocyte-Sparing Radiotherapy and All-Trans Retinoic Acid in Lateralized Oropharyngeal, Laryngeal, and Hypopharyngeal Squamous Cell Carcinoma

Registered drugNo placebo

Evaluation of Lymphocyte-Sparing Radiotherapy and All-Trans Retinoic Acid in Lateralized Oropharyngeal, Laryngeal, and Hypopharyngeal Squamous Cell Carcinoma

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Cetuximab
Sponsor:Centre Leon Berard

Contact Research Centre

Brain neoplasm

Recruiting

Study of tarlatamab and temozolomide combination treatment in adolescents and adults with high grade brain tumors

Registered drugNo placebo

Study of tarlatamab and temozolomide combination treatment in adolescents and adults with high grade brain tumors

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Tarlatamab
Sponsor:Centre Leon Berard

Contact Research Centre

Soft tissue sarcoma

Recruiting

Study of cobimetinib and atezolizumab combination therapy in children and adults with advanced or metastatic soft tissue sarcoma

Registered drugNo placebo

Study of cobimetinib and atezolizumab combination therapy in children and adults with advanced or metastatic soft tissue sarcoma

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Centre Leon Berard

Contact Research Centre

Gastrointestinal stromal tumour

Recruiting

Study on Continuing or Stopping Imatinib in Patients with Advanced or Metastatic Gastrointestinal Stromal Tumors After 10 Years of Treatment

Registered drugNo placebo

Study on Continuing or Stopping Imatinib in Patients with Advanced or Metastatic Gastrointestinal Stromal Tumors After 10 Years of Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Imatinib Mesilate
Sponsor:Centre Leon Berard

Contact Research Centre

Neoplasm

Recruiting

Study of Drug Combination Treatment Based on Tumor Molecular Changes in Patients with Advanced or Metastatic Cancer

Registered drugNo placebo

Study of Drug Combination Treatment Based on Tumor Molecular Changes in Patients with Advanced or Metastatic Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cabozantinib
Sponsor:Centre Leon Berard

Contact Research Centre

Metastatic neoplasm

Recruiting

Evaluation of drug combination therapy (olaparib, nilotinib, tremelimumab, and durvalumab) for patients with advanced or metastatic solid tumors

Registered drugNo placebo

Evaluation of drug combination therapy (olaparib, nilotinib, tremelimumab, and durvalumab) for patients with advanced or metastatic solid tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:Centre Leon Berard

Contact Research Centre

Seminoma

Recruiting

Study on Reducing Treatment for Stage IIa/IIb Seminoma Using Etoposide, Cisplatin, and Carboplatin in Patients with Tumors Smaller than 3 cm

Registered drugNo placebo

Study on Reducing Treatment for Stage IIa/IIb Seminoma Using Etoposide, Cisplatin, and Carboplatin in Patients with Tumors Smaller than 3 cm

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Centre Leon Berard

Contact Research Centre

Ependymoma

Recruiting

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo

Austria

Participants:0–17 years · 18–64 years
Substances:Cisplatin
Sponsor:Centre Leon Berard

Contact Research Centre

Gastric cancer

Recruiting

Study Comparing Survival in Patients with Advanced or Metastatic Gastric Cancer Treated with Botensilimab and Balstilimab vs. Standard Drug Combination

Registered drugNo placebo